Dr. Reddy's to Acquire Haleon's Nicotinell Global NRT Portfolio (Outside the United States)

June 26, 2024

Dr. Reddy’s Laboratories SA has signed a definitive agreement to purchase Haleon’s Haleon group company Northstar Switzerland SARL to acquire Haleon’s global Nicotinell nicotine replacement therapy (NRT) brand portfolio outside the United States. The deal includes Nicotinell plus local leading brand names (Nicabate, Habitrol, Thrive) and applicable pipeline products, with about GBP 217 million revenue reported for the portfolio in CY23.

Buyers
Dr. Reddy's Laboratories SA, Dr. Reddy's Laboratories Ltd.
Targets
Northstar Switzerland SARL
Sellers
Haleon plc
Location
Switzerland
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.